Nu-Med Plus Announces Computer Based Analyzer for Their Portable Inhaled Nitric Oxide System

SALT LAKE CITY, UT--(Marketwired - May 19, 2015) - Nu-Med Plus, Inc. (OTCBB: NUMD), a medical device development company, announced it has completed the development of a computer based analyzer and calibration software to complement their Portable/Rechargeable Inhaled Nitric Oxide unit. The completion of the analyzer is another step in providing a total solution for the administration of nitric oxide in a non-hospital setting. It is designed to be intuitive and simple to use.

Nitric oxide is a medically essential gas that is presently used in Neonate Hypoxia therapy and may have future applications for a variety of other diseases and complications that are currently being investigated. Jeff Robins, President and CEO of Nu-Med Plus, Inc., commented, "We are excited to have completed our analyzer which in conjunction with our portable inhaled nitric oxide unit will enhance the ability of our system to be used outside of the hospital setting for underserved chronic therapies, laboratories and for applications in developing nations."

About Nu-Med Plus, Inc.

Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed technologies. The strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of nitric oxide gas for therapeutic use. For more company information please visit www.nu-medplus.com.

Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.